In the past couple of weeks, the U.S. Food and Drug Administration has approved two new drugs for the treatment of hepatitis C, a virus that can cause liver damage and cancer.
The new drugs should greatly improve cure rates for the more than three million Americans affected by this potentially fatal disease.
The FDA has approved a new drug for the treatment of hepatitis C, a viral disease that attacks the liver and can lead to cirrhosis and liver cancer.
In the U.S., existing medications cure only about 50 percent of patients.
Dr. Bruce Bacon of Saint Louis University led a clinical trial for the new drug, boceprevir.
Bacon says adding boceprevir to the standard two-drug treatment significantly improved cure rates, especially for patients who have been treated before and failed to recover.
St. Louis Public Radio is a service of the University of Missouri-St. Louis.